Skip to main content
Smart Investors Daily
Gilead Sciences, Inc. logo

NASDAQ · GILD

Gilead Sciences, Inc.

Healthcare · Drug Manufacturers - General

$168.98

Down-$2.45 (-1.45%)

Updated Nov 20, 2026, 1:17 AM

SID Score

7.8/10

Composite research score

Smart Money

50/100

Neutral

Market cap
152.89B
P/E ratio
18.89
Dividend yield
2.33%
52-week range
$120.95 – $176.58
Volume
4.96M
Avg. volume
7.34M

Price performance · GILD

GILD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

GILD closed at $168.98 after 20 trading sessions, up 7.50% for the selected period.

Last close
$168.98
Period change
+7.50%
Period low
$156.04
Period high
$174.48
Daily close
View OHLC price history
GILD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$168.78$170.63$167.36$168.984.96M
Nov 17, 2026$166.12$171.36$165.72$170.266.28M
Nov 16, 2026$171.04$171.7966$166.75$167.584.65M
Nov 13, 2026$168.58$169.1191$166.94$168.083.64M
Nov 12, 2026$171.15$171.695$167.93$167.954.23M
Nov 11, 2026$169.45$170.48$168.37$169.734.88M
Nov 10, 2026$170.15$171.15$167.605$170.874.83M
Nov 9, 2026$169.21$170.11$165.985$169.324.47M
Nov 6, 2026$164.11$169.06$164.00$166.895.82M
Nov 5, 2026$174.54$176.58$167.09$167.5711.36M
Nov 4, 2026$171.89$175.41$168.84$174.489.64M
Nov 3, 2026$170.27$172.00$167.43$167.476.61M
Nov 2, 2026$169.85$172.61$166.38$170.338.88M
Oct 30, 2026$170.25$175.65$169.00$170.6811.43M
Oct 29, 2026$162.89$165.70$160.86$165.618.43M
Oct 28, 2026$157.28$160.83$156.04$159.205M
Oct 27, 2026$156.05$159.28$155.76$159.084.93M
Oct 26, 2026$157.62$159.69$157.5201$158.696.05M
Oct 23, 2026$156.47$157.65$155.76$156.046.07M
Oct 22, 2026$154.24$157.42$153.00$157.196.21M

Latest GILD news

The latest Smart Investors Daily articles mentioning GILD.

GILD research

Overview

Company profile and research snapshot.

Company profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$130.64
Implied upside
—
Analysts
17
GILD recent ratings
DateFirmRatingTarget
Nov 16, 2026BarclaysEqual-Weight—
Oct 30, 2026ScotiabankSector Outperform—
Oct 30, 2026RBC CapitalSector Perform—
Oct 30, 2026Truist SecuritiesBuy—
Oct 30, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®

FOSTER CITY, Calif., November 12, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new collaboration with TelevisaUnivision and the 27th Latin GRAMMY Awards that will bring HIV prevention awareness into one of the most prominent cultural moments for Latino audiences.

Yahoo · Nov 11, 2026

Gilead (GILD) Stock Still Looks Undervalued On Its 205% Run

Gilead Sciences has ridden a powerful run in recent years, with the stock now trading near US$170.87, so the key question is whether that share price still matches what its cash flows can support. With major HIV and liver disease programs in the spotlight again, investors are increasingly asking how the company’s current valuation lines up against the cash the business can realistically generate. Over the past 5 years the stock has returned about 205.2%, which puts a lot of accumulated...

Yahoo · Nov 11, 2026

Gilead Sciences (GILD) Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills

Gilead Sciences (NasdaqGS:GILD) reported PURPOSE 5 trial data showing twice-yearly injectable lenacapavir for HIV prevention outperformed daily oral PrEP on persistence. The PURPOSE 5 study found higher adherence and zero HIV infections in the lenacapavir group compared with oral prevention medicines. Researchers described PURPOSE 5 as the first trial built to directly compare long acting injectable PrEP against daily oral HIV prevention regimens. The superior persistence and zero HIV cases...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.